Compendium of Cancer Genome Aberrations

Volunteer Assignments and Opportunities: Difference between revisions

← Older editNewer edit →
VisualWikitext
FQuintero (talk | contribs)
editor
355 edits
No edit summary
Snehal.Patel (talk | contribs)
editor
270 edits
No edit summary
(83 intermediate revisions by 6 users not shown)
Line 24: Line 24:
|
|
|
|
|PENDING/COMPLETE??
|complete
|
|
|FQR
|FQR
Line 34: Line 34:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 44: Line 44:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 54: Line 54:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
|
|8/4/2020 before submission
|
|
|-
|-
|    Essential  Thrombocythaemia (ET)||Disease
|    Essential  Thrombocythaemia (ET)||Disease
|Rebecca Smith (trainee) + faculty TBD
|Rebecca Smith (trainee) + Fabiola Quintero-Rivera
|
|
|
|
|PENDING
|complete/pending faculty review
|
|
|FQR
|FQR
Line 71: Line 71:
|-
|-
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|Mark Evans (trainee), Fabiola Quintero-Rivera
|(trainee), Daynna J.Wolff
|
|
|
|
|PENDING
|pending faculty review
|
|
|FQR
|FQR
Line 81: Line 81:
|-
|-
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|Mark Evans (trainee)+ Fabiola Quintero-Rivera
|Thomas Lee
|
|8/17/2020
|
|9/7/2020
|PENDING
|complete
|
|
|FQR
|FQR
Line 90: Line 90:
|
|
|-
|-
|'''''Mastocytosis'''''||'''''Overview'''''||
|'''''Mastocytosis'''''||'''''Overview'''''||'''Shashi Shetty, Ph.D.'''
|
|
|
|
|
|complete
| ||FQR
| ||FQR
|
|
Line 99: Line 99:
|-
|-
|    Cutaneous  Mastocytosis||Disease
|    Cutaneous  Mastocytosis||Disease
|Thuy Phung
|Thuy Phung/Shuo-Shawn Liu
|
|
|
|
|PENDING
|complete/pending adding content online as of 2/4/21
|
|
|FQR
|FQR
Line 112: Line 112:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 119: Line 119:
|-
|-
|    Mast Cell Sarcoma||Disease
|    Mast Cell Sarcoma||Disease
|Thuy Phung
|Thuy Phung +Jordan Lowery
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 131: Line 131:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 224: Line 224:
|    Juvenile  Myelomonocytic Leukemia (JMML)||Disease||Sarah Rapisardo
|    Juvenile  Myelomonocytic Leukemia (JMML)||Disease||Sarah Rapisardo
|
|
|
|9/1/20
|PENDING
|PENDING
|
|
Line 234: Line 234:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 243: Line 243:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 251: Line 251:
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek?
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek?
|
|
|
|9/1/20
|
|pending
|
|
|FQR
|FQR
Line 260: Line 260:
|    Myelodysplastic  Syndrome (MDS) with Single Lineage Dysplasia||Disease||Xiaoli Du(trainee) +Teresa Smolarek
|    Myelodysplastic  Syndrome (MDS) with Single Lineage Dysplasia||Disease||Xiaoli Du(trainee) +Teresa Smolarek
|
|
|
|9/1/20
|PENDING
|PENDING
|
|
Line 285: Line 285:
|
|
|-
|-
|    Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|
|
|
|9/1/20
|PENDING
|PENDING
|
|
Line 296: Line 296:
|    Myelodysplastic  Syndrome (MDS) with Excess Blasts||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|    Myelodysplastic  Syndrome (MDS) with Excess Blasts||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|
|
|
|9/1/20
|PENDING
|PENDING
|
|
Line 315: Line 315:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 323: Line 323:
|    Refractory Cytopenia  of Childhood||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|    Refractory Cytopenia  of Childhood||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|
|
|
|9/1/20
|PENDING
|PENDING
|
|
Line 344: Line 344:
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|
|04/26/2021 -MS (re-review)
|
|
|-
|-
Line 352: Line 352:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|03/01/2021-MS (re-review)
|
|
|-
|-
Line 360: Line 360:
|PENDING
|PENDING
| ||JH / MS
| ||JH / MS
|
|04/26/2021 -MS (re-review)
|
|
|-
|-
Line 366: Line 366:
|
|
|
|
|PENDING
|Complete
| ||JH / MS
| ||JH / MS
|
|03/01/2021-MS
|
|
|-
|-
Line 374: Line 374:
|
|
|
|
|PENDING
|Complete
| ||JH / MS
|02/03/2021||JH / MS
|
|
|
|
Line 382: Line 382:
|
|
|
|
|PENDING
|Complete
| ||JH / MS
| ||JH / MS
|
|03/02/2021-MS
|
|
|-
|-
Line 392: Line 392:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|03/02/2021-MS (re-review)
|
|
|-
|-
Line 400: Line 400:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|04/26/2021 -MS (re-review)
|
|
|-
|-
Line 409: Line 409:
|
|
|JH / MS
|JH / MS
|
|03/01/2021-MS (re-review)
|
|
|-
|-
Line 417: Line 417:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|04/26/2021-MS (re-review)
|
|
|-
|-
Line 425: Line 425:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|03/01/2021-MS (re-review)
|
|
|-
|-
Line 433: Line 433:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|03/01/2021-MS (re-review)
|
|
|-
|-
Line 441: Line 441:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|03/01/2021-MS (re-review)
|
|
|-
|-
Line 449: Line 449:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|02/24/2021-MS (re-review)
|
|
|-
|-
Line 674: Line 674:
| ||JH / MS
| ||JH / MS
|
|
|Check reference format
|
|-
|-
|    Mixed Phenotype Acute Leukemia (MPAL),  T/Myeloid, Not Otherwise Specified||Disease||Fabiola Quintero-Rivera
|    Mixed Phenotype Acute Leukemia (MPAL),  T/Myeloid, Not Otherwise Specified||Disease||Fabiola Quintero-Rivera
Line 684: Line 684:
|
|
|-
|-
|    ??Mixed-Phenotype Acute Leukaemia, Not  Otherwise Specified (NOS), Rare Types||Disease||
|    Mixed-Phenotype Acute Leukemia, Not  Otherwise Specified (NOS), Rare Types||Disease||Daynna Wolff+ Elicia Goodale (resident)
|
|
|
|
|??
|PENDING
| ||JH / MS
| ||JH / MS
|
|
|
|
|-
|-
|    ??Acute Leukaemias of Ambiguous Lineage,  Not Otherwise Specified (NOS)||Disease||
|    Acute Leukemias of Ambiguous Lineage,  Not Otherwise Specified (NOS)||Disease||Daynna Wolff+Madison Hannay or Elicia Goodale (residents)
|
|
|
|
|??
|PENDING
| ||JH / MS
| ||JH / MS
|
|
Line 757: Line 757:
|
|
|-
|-
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain + Yassmine Akkari
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
Line 774: Line 774:
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||Marilena Melas + Yassmine Akkari
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||Afia Hasnain + Yassmine Akkari
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
Line 801: Line 801:
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||Binu Porath + Linda Cooley
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||Binu Porath + Linda Cooley
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
Line 826: Line 826:
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||Holli Drendel
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||Holli Drendel
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
|
|
|-
|-
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
|Disease
|Diana Rush
|
|
|
|
|PENDING
|
|
| ||YA
|YA
|
|
|
|NON-WHO ENTITY
|-
|-
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
|Disease
|Celeste Eno
|
|
|
|
|PENDING
|
|
| ||YA
|YA
|
|
|
|NON-WHO ENTITY
|-
|-
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||
|B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
|Disease
|Marilena Melas
|
|
|
|
|PENDING
|
|
| ||YA
|YA
|
|
|
|NON-WHO ENTITY
|-
|-
|B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
|B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
|Disease
|Disease
|Helene Bruyere
|Chenkai Ma
|
|
|
|
Line 877: Line 886:
|NON-WHO ENTITY
|NON-WHO ENTITY
|-
|-
| || ||
|B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
|Disease
|Celeste Eno
|
|
|
|
|PENDING
|
|
| ||
|YA
|
|
|
|NON-WHO ENTITY
|-
|-
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|Disease
|Alaa Koleilat
|
|
|
|
|PENDING
|
|
| ||Snehal Patel (SP)
|YA
|
|
|
|NON-WHO ENTITY
|-
|-
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Honey Reddi
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||Fei Yang
|
|
|
|
|PENDING
|PENDING
|
| ||YA
|SP
|
|
|
|
|-
|-
|       Monoclonal B-cell  Lymphocytosis||Disease||Honey Reddi
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||Fei Yang
|
|
|
|
|PENDING
|PENDING
|
| ||YA
|SP
|
|
|
|
|-
|-
|B-cell Prolymphocytic Leukemia||Disease||Honey Reddi
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
|
|
|
|
|PENDING
|PENDING
| ||YA
|
|
|SP
|
|
|-
| || ||
|
|
|-
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
|
|
|
|
|Complete
| ||
|
|
|SP
|
|
|Malini to review
|-
|-
|Hairy Cell Leukemia||Disease||Snehal Patel
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||
|
|
|
|
|
|Complete
| ||Snehal Patel (SP)
|
|
|SP
|
|
|Malini to review
|-
|-
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||
|
|
|
|
|
|Complete
|
|
|SP
|SP
|
|
|Malini to review
|
|-
|-
|    Splenic Diffuse Red  Pulp Small B-cell Lymphoma||Disease||Snehal Patel
|       Monoclonal B-cell Lymphocytosis||Disease||
|
|
|
|
|
|Complete
|
|
|SP
|SP
|
|
|Malini to review
|
|-
|-
|    Hairy Cell Leukemia Variant||Disease||Snehal Patel
|B-cell Prolymphocytic Leukemia||Disease||
|
|
|
|
|
|Complete
|
|
|SP
|SP
|
|
|Malini to review
|
|-
|-
|Lymphoplasmacytic Lymphoma||Disease||Honey Reddi
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
|
|
|
|
|PENDING
|Complete
|
|
|SP
|SP
Line 974: Line 984:
|
|
|-
|-
|   Waldenstrom  Macroglobulinemia||Disease||Honey Reddi
|Hairy Cell Leukemia||Disease||Snehal Patel
|
|
|
|
|PENDING
|Complete
|
|
|SP
|SP
Line 983: Line 993:
|
|
|-
|-
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
|
|
|
|
|Complete
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
|    Splenic Diffuse Red  Pulp Small B-cell Lymphoma||Disease||Snehal Patel
|
|
|
|
|Complete
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|    Mu Heavy Chain Disease||Disease||
|    Hairy Cell Leukemia Variant||Disease||Snehal Patel
|
|
|
|
|Complete
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|   Gamma Heavy Chain  Disease||Disease||
|Lymphoplasmacytic Lymphoma||Disease||
|
|
|
|
|
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|    Alpha Heavy Chain Disease||Disease||
|   Waldenstrom Macroglobulinemia||Disease||
|
|
|
|
|
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|   Non-IgM Monoclonal  Gammopathy of Undetermined Significance||Disease||Zhenya Tang
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|    Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
|    Mu Heavy Chain  Disease||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|-
|   Gamma Heavy Chain  Disease||Disease||Manisha Sutariya
|
|
|Complete
|5/26/2021||SP
|
|
|
|
|-
|-
|    Plasma Cell Myeloma Variants||Disease||Zhenya Tang
|    Alpha Heavy Chain Disease||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|    Plasmacytoma||Disease||Zhenya Tang
|Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
|
|
|
|
Line 1,068: Line 1,087:
|
|
|-
|-
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
|   Non-IgM Monoclonal  Gammopathy of Undetermined Significance||Disease||Zhenya Tang
|
|
|
|
|PENDING
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|           Primary  Amyloidosis||Disease||
|    Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
|
|
|
|
|PENDING
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|           Light Chain  and Heavy Chain Deposition Disease||Disease||
|    Plasma Cell Myeloma Variants||Disease||Fariborz Rashid-Kolvear
|
|
|
|
|PENDING
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
|    Plasmacytoma||Disease||Zhenya Tang
|
|
|
|
|PENDING
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|         POEMS Syndrome||Disease||
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
|
|
|
|
Line 1,108: Line 1,131:
|
|
|-
|-
|         TEMPI Syndrome||Disease||
|           Primary  Amyloidosis||Disease||
|
|
|
|
Line 1,116: Line 1,139:
|
|
|-
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Zhenya Tang & Trainee
|           Light Chain and Heavy Chain Deposition Disease||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|Nodal Marginal Zone Lymphoma||Disease||
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
|
|
|
|
Line 1,133: Line 1,155:
|
|
|-
|-
|    Paediatric Nodal  Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|         POEMS Syndrome||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|Follicular Lymphoma||Disease||Ruthann Pfau
|         TEMPI Syndrome||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|    Testicular Follicular Lymphoma||Disease||Ruthann Pfau
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee, trainee)/Fabiola Quintero-Rivera
|
|3/9/21
|
|
|PENDING
|PENDING
Line 1,160: Line 1,180:
|
|
|-
|-
|    In Situ Follicular  Neoplasia||Disease||Ruthann Pfau
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
|
|
|Complete
|5/28/2021||SP
|
|
|
|
|PENDING
|-
|    Paediatric Nodal  Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|
|
|
|Complete
|11/11/2020
|SP
|SP
|
|
|
|
|-
|-
|    Duodenal-Type  Follicular Lymphoma||Disease||Ruthann Pfau
|Follicular Lymphoma||Disease||Ruthann Pfau
|
|
|
|
Line 1,178: Line 1,206:
|
|
|-
|-
|Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|    Testicular Follicular Lymphoma||Disease||Ruthann Pfau
|
|
|
|
Line 1,187: Line 1,215:
|
|
|-
|-
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||
|    In Situ Follicular  Neoplasia||Disease||Ruthann Pfau
|
|
|
|PENDING
|
|SP
|
|
|-
|    Duodenal-Type  Follicular Lymphoma||Disease||Ruthann Pfau
|
|
|PENDING
|
|SP
|
|
|-
|Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|
|
|
|
| ||SP
|Complete
|8/16/2020
|SP
|
|
|
|
|-
|-
|Primary Cutaneous Follicle Centre Lymphoma||Disease||
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||Afia Hasnaid
|
|
|9/30/20
|Complete
|5/26/2021||SP
|
|
|
|
|-
|Primary Cutaneous Follicle Centre Lymphoma||Disease||Shivani Golem
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,212: Line 1,267:
|
|
|-
|-
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||Mahsa Khanlari
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||
|
|
|
|
|8/31/20
|PENDING
|
|
|SP
|SP
Line 1,221: Line 1,276:
|
|
|-
|-
|    In Situ Mantle Cell  Neoplasia||Disease||Mahsa Khanlari
|    In Situ Mantle Cell  Neoplasia||Disease||
|
|
|
|
|8/15/20
|PENDING
|
|
|SP
|SP
Line 1,383: Line 1,438:
|
|
|-
|-
|Burkitt Lymphoma||Disease||
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|3/11/21
|
|
|
|PENDING
|
| ||GC
| ||GC
|
|
|
|
Line 1,487: Line 1,542:
|
|
|-
|-
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee)
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,547: Line 1,602:
|
|
|
|
|PENDING
|Complete
|
|1/21/2021
|SP
|SP
|
|
Line 1,583: Line 1,638:
|
|
|
|
|PENDING
|Complete
| ||SP
|1/21/2021
|SP
|
|
|
|
Line 1,596: Line 1,652:
|
|
|-
|-
|Mycosis Fungoides||Disease||
|Mycosis Fungoides||Disease||Daynna Wolff, Jane Scribner (trainee)
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|Sézary Syndrome||Disease||
|Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee)
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,710: Line 1,766:
|
|
|-
|-
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease||
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease||Hans Hamnvåg
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,757: Line 1,813:
|
|
|
|
| ||Associate Editor??
| ||Greg Corboy (GC)
|
|
|
|
Line 1,765: Line 1,821:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,773: Line 1,829:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,781: Line 1,837:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,789: Line 1,845:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,797: Line 1,853:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,805: Line 1,861:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,813: Line 1,869:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,821: Line 1,877:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,829: Line 1,885:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,837: Line 1,893:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,848: Line 1,904:
|PENDING
|PENDING
|
|
|
|GC
|
|
|
|
Line 1,856: Line 1,912:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,864: Line 1,920:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,872: Line 1,928:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,880: Line 1,936:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,888: Line 1,944:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,896: Line 1,952:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,904: Line 1,960:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,912: Line 1,968:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,920: Line 1,976:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,928: Line 1,984:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,936: Line 1,992:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,944: Line 2,000:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,952: Line 2,008:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,960: Line 2,016:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,968: Line 2,024:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,976: Line 2,032:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,984: Line 2,040:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 2,377: Line 2,433:
|
|
|
|
|
|
|
|
|-
|-
|KMT2A
|KMT2A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|DEK
|DEK
|
|Wahab A. Khan
|
|
|
|
|
|Pending
|
|
|
|
|
|
|
|
|-
|-
|NUP214
|NUP214
|
|Wahab A. Khan
|
|
|
|
|
|Pending
|
|
|
|
Line 2,511: Line 2,567:
|-
|-
|WT1
|WT1
|DONE
|
|
|
|
|
|DONE
|
|
|
|
|
Line 2,651: Line 2,707:
|-
|-
|ASXL1
|ASXL1
|DONE
|
|
|
|
|
|DONE
|
|
|
|
|
Line 2,700: Line 2,756:
|
|
|-
|-
|
|BRCA1
|
|
|
|
Line 2,710: Line 2,766:
|
|
|-
|-
|
|BRCA2
|
|
|
|
Retrieved from "https://content.ccga.io/index.php/Volunteer_Assignments_and_Opportunities"